Amelogenin is a negative regulator of osteoclastogenesis via downregulation of RANKL, M-CSF and fibronectin expression in osteoblasts

Miyuki Nishiguchi; Kenji Yuasa; Kan Saito; Emiko Fukumoto; Aya Yamada; Tomokazu Hasegawa; Keigo Yoshizaki; Yoko Kamasaki; Kazuaki Nonaka; Taku Fujiwara; Satoshi Fukumoto

doi:10.1016/j.archoralbio.2006.09.016

Amelogenin is a negative regulator of osteoclastogenesis via downregulation of RANKL, M-CSF and fibronectin expression in osteoblasts

Miyuki Nishiguchi, Kenji Yuasa, Kan Saito, Emiko Fukumoto, Aya Yamada, Tomokazu Hasegawa, Keigo Yoshizaki, Yoko Kamasaki, Kazuaki Nonaka, Taku Fujiwara, Satoshi Fukumoto

Research output: Contribution to journal › Article › peer-review

27 Citations (Scopus)

Abstract

Amelogenin is a novel enamel matrix protein. Knockout mice showed enhanced osteoclast formation and resorption of tooth cementum. This study investigated the effects of amelogenin on osteoclastogenesis. In co-cultures with calvaria osteoblasts and purified bone marrow cells, amelogenin inhibited osteoclastogenesis dramatically. Furthermore, amelogenin inhibited the expression of receptor activator of nuclear factor κB ligand (RANKL), macrophage-colony stimulating factor (M-CSF) and fibronectin in osteoblasts, while RANKL expression was induced by fibronectin and inhibited by treatment with fibronectin small interfering RNA. These results suggest that the inhibitory effects of amelogenin on osteoclastogenesis lead to downregulation of RANKL, M-CSF and fibronectin production in osteoblasts.

Original language	English
Pages (from-to)	237-243
Number of pages	7
Journal	Archives of Oral Biology
Volume	52
Issue number	3
DOIs	https://doi.org/10.1016/j.archoralbio.2006.09.016
Publication status	Published - 2007 Mar

Keywords

Amelogenin
Fibronectin
M-CSF
Osteoblast
Osteoclast
RANKL

Access to Document

10.1016/j.archoralbio.2006.09.016

Cite this

Nishiguchi, M., Yuasa, K., Saito, K., Fukumoto, E., Yamada, A., Hasegawa, T., Yoshizaki, K., Kamasaki, Y., Nonaka, K., Fujiwara, T., & Fukumoto, S. (2007). Amelogenin is a negative regulator of osteoclastogenesis via downregulation of RANKL, M-CSF and fibronectin expression in osteoblasts. Archives of Oral Biology, 52(3), 237-243. https://doi.org/10.1016/j.archoralbio.2006.09.016

@article{3f899dd612a5474e9d4fe9b4d052988b,

title = "Amelogenin is a negative regulator of osteoclastogenesis via downregulation of RANKL, M-CSF and fibronectin expression in osteoblasts",

abstract = "Amelogenin is a novel enamel matrix protein. Knockout mice showed enhanced osteoclast formation and resorption of tooth cementum. This study investigated the effects of amelogenin on osteoclastogenesis. In co-cultures with calvaria osteoblasts and purified bone marrow cells, amelogenin inhibited osteoclastogenesis dramatically. Furthermore, amelogenin inhibited the expression of receptor activator of nuclear factor κB ligand (RANKL), macrophage-colony stimulating factor (M-CSF) and fibronectin in osteoblasts, while RANKL expression was induced by fibronectin and inhibited by treatment with fibronectin small interfering RNA. These results suggest that the inhibitory effects of amelogenin on osteoclastogenesis lead to downregulation of RANKL, M-CSF and fibronectin production in osteoblasts.",

keywords = "Amelogenin, Fibronectin, M-CSF, Osteoblast, Osteoclast, RANKL",

author = "Miyuki Nishiguchi and Kenji Yuasa and Kan Saito and Emiko Fukumoto and Aya Yamada and Tomokazu Hasegawa and Keigo Yoshizaki and Yoko Kamasaki and Kazuaki Nonaka and Taku Fujiwara and Satoshi Fukumoto",

note = "Funding Information: The authors would like to thank Konishi Ikuri for excellent technical assistance. This work was supported, in part, by grants-in-aid for Research Fellows of the Japan Society for the Promotion of Science from the Ministry of Education, Science and Culture of Japan, nos. 15689025 and 17689058. ",

year = "2007",

month = mar,

doi = "10.1016/j.archoralbio.2006.09.016",

language = "English",

volume = "52",

pages = "237--243",

journal = "Archives of Oral Biology",

issn = "0003-9969",

publisher = "Elsevier Ltd.",

number = "3",

}

Nishiguchi, M, Yuasa, K, Saito, K, Fukumoto, E, Yamada, A, Hasegawa, T, Yoshizaki, K, Kamasaki, Y, Nonaka, K, Fujiwara, T & Fukumoto, S 2007, 'Amelogenin is a negative regulator of osteoclastogenesis via downregulation of RANKL, M-CSF and fibronectin expression in osteoblasts', Archives of Oral Biology, vol. 52, no. 3, pp. 237-243. https://doi.org/10.1016/j.archoralbio.2006.09.016

TY - JOUR

T1 - Amelogenin is a negative regulator of osteoclastogenesis via downregulation of RANKL, M-CSF and fibronectin expression in osteoblasts

AU - Nishiguchi, Miyuki

AU - Yuasa, Kenji

AU - Saito, Kan

AU - Fukumoto, Emiko

AU - Yamada, Aya

AU - Hasegawa, Tomokazu

AU - Yoshizaki, Keigo

AU - Kamasaki, Yoko

AU - Nonaka, Kazuaki

AU - Fujiwara, Taku

AU - Fukumoto, Satoshi

N1 - Funding Information: The authors would like to thank Konishi Ikuri for excellent technical assistance. This work was supported, in part, by grants-in-aid for Research Fellows of the Japan Society for the Promotion of Science from the Ministry of Education, Science and Culture of Japan, nos. 15689025 and 17689058.

PY - 2007/3

Y1 - 2007/3

N2 - Amelogenin is a novel enamel matrix protein. Knockout mice showed enhanced osteoclast formation and resorption of tooth cementum. This study investigated the effects of amelogenin on osteoclastogenesis. In co-cultures with calvaria osteoblasts and purified bone marrow cells, amelogenin inhibited osteoclastogenesis dramatically. Furthermore, amelogenin inhibited the expression of receptor activator of nuclear factor κB ligand (RANKL), macrophage-colony stimulating factor (M-CSF) and fibronectin in osteoblasts, while RANKL expression was induced by fibronectin and inhibited by treatment with fibronectin small interfering RNA. These results suggest that the inhibitory effects of amelogenin on osteoclastogenesis lead to downregulation of RANKL, M-CSF and fibronectin production in osteoblasts.

AB - Amelogenin is a novel enamel matrix protein. Knockout mice showed enhanced osteoclast formation and resorption of tooth cementum. This study investigated the effects of amelogenin on osteoclastogenesis. In co-cultures with calvaria osteoblasts and purified bone marrow cells, amelogenin inhibited osteoclastogenesis dramatically. Furthermore, amelogenin inhibited the expression of receptor activator of nuclear factor κB ligand (RANKL), macrophage-colony stimulating factor (M-CSF) and fibronectin in osteoblasts, while RANKL expression was induced by fibronectin and inhibited by treatment with fibronectin small interfering RNA. These results suggest that the inhibitory effects of amelogenin on osteoclastogenesis lead to downregulation of RANKL, M-CSF and fibronectin production in osteoblasts.

KW - Amelogenin

KW - Fibronectin

KW - M-CSF

KW - Osteoblast

KW - Osteoclast

KW - RANKL

UR - http://www.scopus.com/inward/record.url?scp=33846226701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846226701&partnerID=8YFLogxK

U2 - 10.1016/j.archoralbio.2006.09.016

DO - 10.1016/j.archoralbio.2006.09.016

M3 - Article

C2 - 17101114

AN - SCOPUS:33846226701

SN - 0003-9969

VL - 52

SP - 237

EP - 243

JO - Archives of Oral Biology

JF - Archives of Oral Biology

IS - 3

ER -

Amelogenin is a negative regulator of osteoclastogenesis via downregulation of RANKL, M-CSF and fibronectin expression in osteoblasts

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this